WO2007119692A1 - MÉTHODE D'INHIBITION DE LA PROLIFÉRATION DE CELLULES CANCÉREUSES PAR RÉGULATION DE L'EXPRESSION D'eIF4H - Google Patents

MÉTHODE D'INHIBITION DE LA PROLIFÉRATION DE CELLULES CANCÉREUSES PAR RÉGULATION DE L'EXPRESSION D'eIF4H Download PDF

Info

Publication number
WO2007119692A1
WO2007119692A1 PCT/JP2007/057733 JP2007057733W WO2007119692A1 WO 2007119692 A1 WO2007119692 A1 WO 2007119692A1 JP 2007057733 W JP2007057733 W JP 2007057733W WO 2007119692 A1 WO2007119692 A1 WO 2007119692A1
Authority
WO
WIPO (PCT)
Prior art keywords
eif
cancer
expression
gene
isoform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/057733
Other languages
English (en)
Japanese (ja)
Inventor
Hideaki Shimada
Kazuyuki Matsushita
Takeshi Tomonaga
Fumio Nomura
Takenori Ochiai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiba University NUC
Original Assignee
Chiba University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiba University NUC filed Critical Chiba University NUC
Publication of WO2007119692A1 publication Critical patent/WO2007119692A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Definitions

  • the measurement of the expression level of the eIF-4H gene can be quantitative, semi-quantitative, or qualitative depending on the measurement method and principle.
  • suppression of the expression can be detected significantly by qualitative determination.
  • the selection of the substance that suppresses the expression level can be performed by, for example, comparing with the expression level of the eIF_4H gene in the absence of the test substance.
  • Tumor cells LOVO and RKO, and lung fibroblast cell line MRC5 were purchased from RIKEN Cell Bank (Tsukuba, Ibaraki, Japan).
  • Tumor cells LOVO and RKO, and normal cells MRC5 are 10% fetal bovine serum, lOOU / ml penicillin and 100 g / ml streptomycin, respectively (all purchased from Invitrogen, Carlsbad, CA) Cultivation was carried out at 37 ° C under 5% CO conditions using RPMI-1640 and IMDM.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a pour objet de permettre une détection, un diagnostic et un traitement plus efficaces et plus sûrs des cancers, en particulier, des cancers digestifs tel que le cancer du côlon, et de fournir diverses biomolécules qui sont utilisables pour développer des systèmes de diagnostic génétique et des études cliniques de thérapie génique contre les cancers susdécrits. L'invention concerne donc une méthode d'inhibition de la prolifération de cellules cancéreuses qui consiste à réguler l'expression d'eIF-4H; une composition médicinale qui contient un ARNsi spécifique de l'eIF-4H en tant qu'ingrédient actif; un procédé de criblage d'une substance présentant une activité d'inhibition de la prolifération de cellules cancéreuses basé sur le degré d'expression d'eIF-4H; etc.
PCT/JP2007/057733 2006-04-12 2007-04-06 MÉTHODE D'INHIBITION DE LA PROLIFÉRATION DE CELLULES CANCÉREUSES PAR RÉGULATION DE L'EXPRESSION D'eIF4H Ceased WO2007119692A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006109310A JP4806772B2 (ja) 2006-04-12 2006-04-12 ｅＩＦ４Ｈ発現抑制による癌細胞の増殖阻害方法
JP2006-109310 2006-04-12

Publications (1)

Publication Number Publication Date
WO2007119692A1 true WO2007119692A1 (fr) 2007-10-25

Family

ID=38609452

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/057733 Ceased WO2007119692A1 (fr) 2006-04-12 2007-04-06 MÉTHODE D'INHIBITION DE LA PROLIFÉRATION DE CELLULES CANCÉREUSES PAR RÉGULATION DE L'EXPRESSION D'eIF4H

Country Status (2)

Country Link
JP (1) JP4806772B2 (fr)
WO (1) WO2007119692A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103421792A (zh) * 2013-06-21 2013-12-04 浙江理工大学 真核生物翻译起始因子4H（eIF4H）基因沉默抑制肿瘤细胞生长的方法及其应用
CN111471679A (zh) * 2018-12-19 2020-07-31 复旦大学 干预eif4h剪接亚型的寡聚核苷酸及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004298112A (ja) * 2003-03-31 2004-10-28 Japan Science & Technology Agency ヒト固形癌抗原ペプチドとこれをコードするポリヌクレオチド、並びにそれらの利用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004298112A (ja) * 2003-03-31 2004-10-28 Japan Science & Technology Agency ヒト固形癌抗原ペプチドとこれをコードするポリヌクレオチド、並びにそれらの利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOMONAGA T. ET AL.: "Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis", CLINICAL CANCER RESEARCH, vol. 10, no. 6, 2004, pages 2007 - 2014, XP002340980 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103421792A (zh) * 2013-06-21 2013-12-04 浙江理工大学 真核生物翻译起始因子4H（eIF4H）基因沉默抑制肿瘤细胞生长的方法及其应用
CN103421792B (zh) * 2013-06-21 2015-03-25 浙江理工大学 真核生物翻译起始因子4H（eIF4H）基因沉默抑制肿瘤细胞生长的方法及其应用
CN111471679A (zh) * 2018-12-19 2020-07-31 复旦大学 干预eif4h剪接亚型的寡聚核苷酸及其应用

Also Published As

Publication number Publication date
JP4806772B2 (ja) 2011-11-02
JP2007277204A (ja) 2007-10-25

Similar Documents

Publication Publication Date Title
Weigand et al. Impact of USP8 gene mutations on protein deregulation in Cushing disease
US9587239B2 (en) Methods of identifying and treating glioblastoma
KR102341336B1 (ko) 만성간질환의 예후 예측용 바이오마커 조성물
JP2011501741A (ja) がんの診断および治療のためのｔａｚ／ｗｗｔｒ１
JPWO2019093502A1 (ja) がん促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法
WO2018223867A1 (fr) Marqueur du cancer de la prostate spop et son utilisation dans le guidage d'une thérapie tumorale
Yokomori et al. Elevated expression of caveolin-1 at protein and mRNA level in human cirrhotic liver: relation with nitric oxide
JP6464436B2 (ja) 受容体共役タンパク質キナーゼ−３（ｒｉｐ３）発現促進剤を有効成分として含む抗癌補助用組成物、受容体共役タンパク質キナーゼ−３（ｒｉｐ３）の発現を促して抗癌剤感受性を増進させる抗癌補助剤のスクリーニング方法及び抗癌剤感受性のモニターリング方法
KR101315570B1 (ko) 간암 진단 마커 및 치료제로서의 ｎｌｋ
JP2008516895A (ja) Ｗｎｔタンパク質ならびに癌の検出および治療の方法
JP4806772B2 (ja) ｅＩＦ４Ｈ発現抑制による癌細胞の増殖阻害方法
US10688197B2 (en) Non-alcoholic fatty liver regulator 14-3-3 protein
KR101861260B1 (ko) 세포 노화 측정용 바이오마커 조성물 및 진단방법
WO2019031637A1 (fr) Gènes marqueurs du cancer pour le cancer non mutationnel p53, et procédé de dépistage d'agent thérapeutique
CN111630185A (zh) 包含pmvk作为活性成分的用于诊断耐放射癌症或预测放射疗法预后的生物标志物组合物
Orii et al. Altered post-translational modification of redox factor 1 protein in human uterine smooth muscle tumors
JP7250307B2 (ja) 子宮癌の発症、転移又は再発の予測方法
WO2013122321A1 (fr) Utilisation de hdac6 en tant que marqueur d'hépatome et agent thérapeutique
US20180207294A1 (en) Non-alcoholic fatty liver regulating factor 14-3-3 protein
KR102025005B1 (ko) 전암성 병변에서 조기 간암을 진단 및 예측할 수 있는 바이오 마커 및 이의용도
KR102055350B1 (ko) 대장암의 항암제 내성 진단용 바이오마커 및 이의 용도
US20210164982A1 (en) Pharmaceutical use of actinin-4 involved in induction of cervical cancer
KR102325972B1 (ko) 간암 치료 반응 예측용 spp1 바이오마커 및 이의 용도
KR101150410B1 (ko) 간암 진단용 마커로서의 ｓ100ｐ의 용도
KR102743789B1 (ko) Csde1을 유효성분으로 포함하는 삼중음성유방암 전이 예측용 바이오마커 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07741169

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07741169

Country of ref document: EP

Kind code of ref document: A1